A Phase 1/2, Double-Blind, Placebo-Controlled Study of the Pharmacokinetics, Safety and Tolerability of GSK3196165 in Combination With Methotrexate Therapy, in Japanese Subjects With Active Moderate-Severe Rheumatoid Arthritis Despite Treatment With Methotrexate
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 24 Jul 2017
At a glance
- Drugs Folic acid (Primary) ; GSK 3196165 (Primary) ; Methotrexate (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions; Pharmacokinetics
- Sponsors GlaxoSmithKline
- 20 Jul 2017 Status changed from recruiting to active, no longer recruiting.
- 26 Jun 2017 Planned End Date changed from 4 Jul 2018 to 29 Dec 2017.
- 26 Jun 2017 Planned primary completion date changed from 4 Jul 2018 to 29 Dec 2017.